Manufacturing Intelligence — June 24, 2026
|
SK pharmteco’s launch of its branded SKyvec™ viral vector platform marks the moment when CGT contract manufacturers stopped competing on raw capacity and started competing on platform identity — even as AI quietly moves from the lab notebook onto the GMP factory floor.
Today’s top developments:
|
What to Watch
- Sangamo asset auction resolution — Watch for final bidder announcements and asset allocation between Eli Lilly and Astellas; the outcome will clarify whether Sangamo’s zinc finger nuclease manufacturing infrastructure and gene regulation IP are absorbed into existing CGT programs or held for out-licensing, with implications for both acquirers’ positioning in non-viral and in vivo gene therapy.
- AI in GMP manufacturing — the regulatory guidance gap — With BIO 2026 panels revealing accelerating AI adoption in CGT process control at firms like Kriya, Opus, and Epicrispr, expect mounting pressure on FDA and EMA to clarify validation expectations for AI-assisted controls. The first warning letter touching an AI-driven manufacturing decision could trigger sector-wide compliance reassessment.
- Radiopharmaceutical capacity race — AdvanCell’s Boston lease adds another entrant to a rapidly crowding field. Watch capital deployment by Eli Lilly, Novartis, and Bristol-Myers Squibb for further site announcements; isotope supply constraints and hot-cell lead times of 18–24 months mean companies securing facilities now will hold first-mover supply advantages by 2028.
- Pfizer’s GMP pathway choice on the Innovent pipeline — Integrating 12 China-originated biologics assets into a Western-compliant supply chain will force a build-versus-partner-versus-validate decision over the next 24 months. The route Pfizer picks will become a template rivals study as onshoring pressure intensifies on China-sourced manufacturing.
This brief highlights the edition’s top stories. Read the full June 24, 2026 edition → for all stories and analysis — or browse the Manufacturing Intelligence archive.